Passwort zurücksetzen

Sino Biological – Driving Discovery, Delivering Life-Changing Biotech Innovations

About Sino Biological

Sino Biological is a global leader in producing high-quality recombinant proteins, antibodies, and cDNA clones for life sciences, biotech, and pharmaceutical industries. With 15+ years of experience, we provide integrated solutions from research and development to full-scale manufacturing to accelerate scientific discovery and drug development.

Our Mission

Advance life science research and improve human health by delivering superior research reagents and contract research organization (CRO) services.

Core Competencies

– Recombinant Protein & Antibody Production: Custom research reagents supporting academic, biotech, and pharma innovation.

– Pre-Clinical Production & CRO: Services supporting hundreds of monoclonal antibody drug candidates.

– Bioprocess Center (USA): GMP-compliant facility specializing in low endotoxin production, high purity proteins, protein interaction analysis, tag removal, buffer screening, and glycosylation studies.

Innovation & Technology

Cutting-edge R&D platforms combined with scalable manufacturing ensure high-throughput, efficient production. Quality control includes biochemical, enzymatic, cellular, molecular, virological, and immunological assays.

Strategic Acquisition

In 2024, acquired SignalChem Biotech Inc., expanding our enzyme portfolio with the world’s largest active kinase catalog and enhanced enzyme assay development services.

Our People & Facilities

– 900+ staff, including 230+ with advanced degrees

– 279,800 sq ft lab/office space

– 75,000 sq ft GMP manufacturing facility

– Global presence: Beijing HQ, subsidiaries in the US, Europe, Japan, and a worldwide distributor network

Clients

Serving academic institutions, biotech startups, and leading pharmaceutical companies worldwide.

Website: www.sinobiological.com

Sino Biological – Driving Discovery, Delivering Life-Changing Biotech Innovations

Check out Sino Biological’s image film here

Call for Abstracts

Registration for the Pitch and Poster Session is now open. The Pitch Session is designed for start-ups and spin-offs, ideally in the pre-seed or seed phase, while the Poster Session is intended for R&D teams presenting innovative projects in the field of Cell and Gene Therapy. Applications will be evaluated based on the maturity of the developed technology, its innovative character, and its transfer and translation potential. Participants in the Pitch Session will have the opportunity to present their technology and receive feedback from both investors and the general audience, and a dedicated Poster Session will take place during the event. Prizes will be awarded to the top contributions: first place in the poster session will receive a surprise gift, and first place in the pitch session will win a ticket to BioVaria 2027 in Munich. Many thanks to the sponsor, BioVaria 2027. The deadline for registration is March 31. Please click the link to be directed to the registration page.

BioVaria

BioVaria targets technology scouts, business developers and investors highlighting commercially attractive licensing opportunities and promising
start‑ups from across Europe. This unique event brings together Europe‘s leading tech transfer professionals, innovators from academia and start-ups with investors and representatives of
the global biotech and pharma industry.

• Scientists, technology transfer professionals, investors and industry scouts
• European technology transfer organizations presenting commercially
attractive licensable technologies and partnership opportunities
• Startup Pitch & Partner featuring some of Europe’s most promising
start‑ups
• Face-to-face discussions with investors and inventors.

BioVaria is Europe’s leading event for innovation in the life sciences. Organized by Ascenion and other European technology transfer companies, it brings together potential licensees and investors from the biotechnology and pharmaceutical industries with scientists, founders and technology transfer experts from all over Europe. On April 27 & 28, 2026, first-class research institutions, universities and university hospitals will present around 70 selected, licensable life science technologies. This year again, projects in early stages of
development will also be presented, including projects from Ascenion’s Life Science Digital Hub, which is funded by GO-Bio initial.

The Startup Pitch & Partner programme at BioVaria has been a special highlight for years: start-ups selected by a jury are given the opportunity to present their projects to international and regional investors and win prize money. Interested start-ups can apply for Startup Pitch & Partner until February 15, 2026.
Register now for BioVaria 2026!

More information at www.biovaria.org

Innovation Award 2026

Innovation Award 2026 of the BioRegions in Germany
Inventive spirit wanted. APPLY NOW!
Supporting innovative inventions

The Working Group of the BioRegions in Germany is the central network of regional initiatives promoting the economic use of modern biotechnology in Germany. Each year, it awards the Innovation Award of the BioRegions in Germany. This year again, the Working Group honors application-oriented ideas with strong implementation potential and presents them at the German Biotechnology Days.

What is being awarded?

The Innovation Award honors innovative ideas that have been patented or submitted for patent application.
The focus is on application-oriented ideas with strong implementation potential and high market opportunities.
The goal is to support outstanding innovations that can make a relevant contribution to the economy and society.

Who can apply?

Scientists from universities and non-university research institutions
Legal entities under public law such as universities, universities of applied sciences, or patent exploitation agencies
Founders of companies that have not yet generated significant revenue and have not transferred substantial company shares to external investors

What is offered?

Invitation of six finalists to the German Biotechnology Days on April 21 and 22, 2026, in Leipzig
Presentation to an international professional audience, the BioRegions network, financiers, and the trade press
Three prizes, each endowed with €2,000
An audience award worth €2,000

Apply now!

Applications are open until February 24, 2026.

Click here to apply.

Innovationspreis 2026 der BioRegionen in Deutschland

Innovationspreis 2026 der BioRegionen in Deutschland
Erfindergeist gesucht. JETZT BEWERBEN!
Förderung innovativer Erfindungen

Der Arbeitskreis der BioRegionen in Deutschland ist das zentrale Netzwerk der regionalen Initiiven zur Förderung der wirtschaftlichen Nutzung moderner Biotechnologien in Deutschland. Er vergibt jährlich den Innovationspreis der BioRegionen in Deutschland. Auch in diesem Jahr prämiert der Arbeitskreis anwendungsorientierte Ideen mit starkem Umsetzungspotenzial und macht diese bei den Deutschen Biotechnologietagen sichtbar.

Was wird ausgezeichnet?
Der Innovationspreis prämiert innovative Ideen, die patentiert sind oder zur Patentierung angemeldet wurden.
Gesucht werden anwendungsorientierte Ideen mit starkem Umsetzungspotenzial und hohen Marktchancen.
Ziel ist es, herausragende Innovationen zu unterstützen, die einen relevanten Beitrag zu Wirtschaft und Gesellschaft leisten können.

Wer kann sich bewerben?

Wissenschaftlerinnen und Wissenschaftler aus Universitäten und außeruniversitären Einrichtungen
Juristische Personen des öffentlichen Rechts wie Universitäten, Fachhochschulen oder Patentverwertungsagenturen
Gründerinnen und Gründer von Unternehmen, die noch keinen relevanten Umsatz erwirtschaftet und keine wesentlichen Unternehmensanteile an externe Kapitalgeber abgegeben haben

Was wird geboten?

Einladung von sechs Finalistinnen und Finalisten zu den Deutschen Biotechnologietagen am 21. und 22. April 2026 in Leipzig
Präsentation vor einem internationalen Fachpublikum, dem BioRegionen-Netzwerk, Finanziers und der Fachpresse
Drei Preise, jeweils dotiert mit 2.000 €
Ein Publikumspreis im Wert von 2.000 €

Jetzt bewerben!
Bewerbungen sind bis 24. Februar 2026 möglich.

Klicken Sie hier zu bewerben.

LeapUp

LeapUp GmbH (formerly biosaxony Management GmbH) empowers founders, startups, and SMEs in the life sciences to take significant steps towards innovation, market entry, commercialization, and growth.

Their mission is to support scientists, companies and startups in the field of life sciences to transform their innovative ideas into scalable business models. Through their projects and world-class services, they help to bridge the gap between idea and realization.

Their portfolio includes acceleration and development services for life science projects, regulatory support, training programs, and events through our in-house academy, as well as the provision of state-of-the-art co-working labs in Leipzig. They are actively expanding their international presence and service, including investor relations and funding opportunities.

Their focus areas include diagnostics, cell and gene therapy, radiopharmacy, smart medical devices, robotics and AI, digital health, and phage therapy.

Click here to visit their website.

Kathrin Schumann

Affiliation:

University of Konstanz

Job Position:

Professor for Immunology

Background: Kathrin Schumann studied biochemistry at the University of Tübingen and obtained her PhD at the Max Planck Institute of Biochemistry in Martinsried. During her postdoc at the University of California, San Francisco, she developed CRISPR technologies for the engineering of primary human T cells. In 2018, she was appointed as Rudolf Mößbauer Tenure Track Assistant Professor of “Engineering Immune Cells for Therapy” at TUM School of Medicine. In 2025, she took up the position of Chair of Immunology at the University of Konstanz.

Tomasz Baran

Affiliation:

FamiCord AG

Background: Tomasz Baran is Chief Medical Officer of FamiCord – the largest cord blood bank in Europe and 3rd largest worldwide. He joined cord blood banking activity in 2010, prior to that he has been holding various position in pharmaceutical industry. In his current role Tomasz is responsible for medical communication on stem cell banking and use in therapies. He presented this topic on several international events – including Cord Blood Connect (USA), Perinatal Stem Cell Conference (USA) and Advanced Therapies (UK). Tomasz is also involved in development of cell&gene therapies manufacturing activity of FamiCord. Tomasz Baran serves ad Board of Directors member at Cord Blood Association (currently incorporated into AABB).

Mike Karl

Affiliation:

TUD Dresden University of Technology, CRTD – Center for Regenerative Therapies Dresden
Deutsches Zentrum für Neurodegenerative Erkrankungen e.V. (DZNE) Dresden
Professor, Retinal Stem Cell Research and Neurogenesis

Background: Prof. Dr. med. Mike O. Karl is a group leader at the German Center for Neurodegenerative Diseases (DZNE) and professor at the Center for Regenerative Therapies Dresden (CRTD), TU Dresden. His research focuses on human retina degeneration and therapy, with a particular emphasis on photoreceptor neurodegeneration, glia biology, and human stem cell–derived cell and organoid technologies as disease and therapy‐validation models. He has made key contributions to understanding cellular mechanisms of retinal degeneration and to the development of human-based translational model systems for age-related macular degeneration and inherited retinal diseases. His work has been recognized by multiple awards in ophthalmology and regenerative medicine, and he actively bridges fundamental discovery with translational and therapeutic innovation.

Ernst Wagner

Affiliation:

Ludwig-Maximilians-Universität (LMU) München

Background: Ernst Wagner is Chair of Pharmaceutical Biotechnology, Department Pharmacy, LMU Munich (since 2001) and member of Munich Center of Nanoscience (CeNS). He was Director Cancer Vaccines, Boehringer Ingelheim 1992-2001 (world-wide first polymer-based gene therapy in 1994), Group Leader at IMP Vienna and the Vienna University Biocenter (1987-1995), postdoc at ETH Zurich (1985-1987), PhD in chemistry (1985, TU Vienna). He is Academician of the European Academy of Sciences, member of College of Fellows of Controlled Release Society (CRS), Honorary Professor at Sichuan U and at Jinan U. He authored ≥ 529 publications, with > 56 000 citations, h-index 119 (GS).

Erfolg gefeiert: CAR FINDER gewinnt bei der Leipziger Gründungsnacht

Wir freuen uns, Sandy Tretbar (Fraunhofer IZI), Projektleiterin von SB-TRACT innerhalb von SaxoCell, zum Gewinn des „Idee“-Preises bei der 10. Leipziger Gründungsnacht mit ihrem innovativen Spin-off-Projekt CAR FINDER zu gratulieren.

Mit einem überzeugenden Pitch und einem visionären Konzept zur schnellen Bewertung von CAR-T-Zellkandidaten konnte Sandy gemeinsam mit ihrem Team die Jury begeistern und sich ein Preisgeld in Höhe von 5.000 € sichern.

CAR FINDER bietet eine Plattform zur raschen Identifizierung und Charakterisierung vielversprechender CAR-Kandidaten für nächste-Generation-Zelltherapieprodukte – und beschleunigt damit deren Entwicklung durch eine umfassende in-vitro-Analyse von CAR-Expression, Signalgebung und CAR-T-Zell-Funktionalität.

Wir freuen uns sehr, dass Sandys wissenschaftliche Exzellenz und ihr unternehmerischer Elan auf diese Weise gewürdigt werden, und blicken gespannt auf die nächsten Schritte in der Entwicklung von CAR FINDER.

Herzlichen Glückwunsch an Sandy und das gesamte CAR FINDER-Team sowie an Fraunhofer AHEAD und alle, die diese vielversprechende Innovation unterstützen. SaxoCell ist stolz darauf, solch inspirierende Talente in unserer Community zu haben!

Celebrating Success: CAR FINDER Wins at the Leipzig Founders Night

We are pleased to congratulate Sandy Tretbar (Fraunhofer IZI), project lead of SB-TRACT within SaxoCell, on winning the “Idea” award at the 10th Leipziger Gründungsnacht with her innovative spin-off project CAR FINDER.

With a strong pitch and a visionary approach to rapid CAR T-cell screening, Sandy and her team impressed the jury and received a prize of €5,000.

CAR FINDER offers a platform for the fast identification and characterization of lead CAR candidates for next-generation cell therapy products — accelerating development through comprehensive in-vitro analysis of CAR expression, signaling, and CAR T-cell functionality.

We are delighted to see Sandy’s entrepreneurial drive and scientific excellence being recognized and are excited to follow the next steps in the CAR FINDER journey.

Warm congratulations to Sandy and the entire CAR FINDER team, as well as to Fraunhofer AHEAD and everyone supporting this highly promising innovation. SaxoCell is proud to have such inspiring talent in our community!

High Attendance at the SaxoCell Patient Day as Part of the UKL Health Forum

Of course — here is a polished English translationLeipzig, 15 November 2025 – During the Cancer Information Day hosted by Leipzig University Hospital, the SaxoCell Cluster presented its own Patient Day and attracted great interest. Numerous visitors took the opportunity to learn more at the SaxoCell booth about new therapy approaches developed in Saxony, which are already benefiting patients with blood cancer today.

Serving as key points of contact, Nicole Modler and Stefanie Binder from SaxoCellutions – the coordination hub of SaxoCell – engaged in many in-depth conversations, answered questions, and provided insights into current developments in cell and gene therapy. The strong engagement from attendees highlighted how essential clear and accessible information about modern treatment options is.

An emotional highlight of the day was a reading by author and former UKL cancer patient Stefan Schwarz from his book “Bis ins Mark” (“To the Core”). With humor, honesty, and heartfelt sincerity, he shared his experiences during treatment – a contribution that moved and encouraged the audience in equal measure.

Scientifically, the event was enriched by two impressive lectures from Leipzig University Hospital: Prof. Ulrich Hacker gave an easy-to-understand overview of personalized cancer medicine, while PD Dr. Vladan Vucinic presented the latest advances in innovative cell therapies as well as current progress within the SaxoCell Cluster.

The consistently well-attended sessions and lively discussions demonstrated both the high demand for information and the trust patients place in advanced therapeutic approaches.

SaxoCell extends its thanks to the University Cancer Center Leipzig (UCCL) and the event management team of UKL for their excellent organization and collaborative partnership in making this valuable Patient Day possible.

BMBF Clusters4Future Meeting 2024

SaxoCell returns from Munich after this year’s Clusters4Future experience exchange.

Over two days, the seven clusters from both the first and second rounds of the competition had the opportunity to network and exchange ideas on key topics like cluster management, sustainability, and industrial collaborations. Representing us were SaxoCell spokesperson Frank Buchholz, along with Maren Henneken and Stefanie Binder from the Hub team.

This year’s hosts were Munich-based clusters MCube and CNATM. In addition to their thematic focuses on mobility and nucleic acid therapies, Best Practices on cluster sustainability, such as those presented by BioRN, were shared. During the panel discussion, participants received valuable insights into attracting young talent and skilled professionals, as well as transitioning Clusters4Future to the second funding phase. An open dialogue with representatives from the BMBF and Projektträger Jülich rounded off the meeting.

As in the past two years, the annual exchange provided an ideal opportunity to gain new insights, learn from one another, and reconnect with long-standing contacts. We’re looking forward to next year!

SaxoCell enters second funding phase!

SaxoCell is pleased to announce that it has been selected by the Federal Ministry of Education and Research (BMBF) and an independent expert jury for a second phase of funding in the Clusters4Future initiative.

We are very happy about this as it highlights the potential and achievements of SaxoCell, a pioneering cluster for innovative cell and gene therapies.

BMBF Clusters4Future press release

TU Dresden press release

University Leipzig press release

Fraunhofer IZI press release

BMBF Clusters4Future Meeting 2024

SaxoCell returns from Munich after this year’s Clusters4Future experience exchange.

Over two days, the seven clusters from both the first and second rounds of the competition had the opportunity to network and exchange ideas on key topics like cluster management, sustainability, and industrial collaborations. Representing us were SaxoCell spokesperson Frank Buchholz, along with Maren Henneken and Stefanie Binder from the Hub team.

This year’s hosts were Munich-based clusters MCube and CNATM. In addition to their thematic focuses on mobility and nucleic acid therapies, Best Practices on cluster sustainability, such as those presented by BioRN, were shared. During the panel discussion, participants received valuable insights into attracting young talent and skilled professionals, as well as transitioning Clusters4Future to the second funding phase. An open dialogue with representatives from the BMBF and Projektträger Jülich rounded off the meeting.

As in the past two years, the annual exchange provided an ideal opportunity to gain new insights, learn from one another, and reconnect with long-standing contacts. We’re looking forward to next year!

SaxoCell Retreat 2024

At the beginning of June, our two-day SaxoCell retreat was a resounding success, offering a perfect blend of productive discussions and engaging activities. PIs and scientists from our projects and platforms, members from the SaxoCell Hub as well as our Scientific Advisory Board representatives gathered at Congress Hotel Chemnitz.

Our agenda was packed with insightful discussions, innovative pitches, and a comprehensive outlook on our future projects and perspectives.

The highlight of our retreat was the team challenge, where we formed eight teams to build spaghetti towers – aiming for the highest – fostering creativity and teamwork. The winning tower measured 70 centimetres! There was also a winner of hearts which was not as high but very stable and ready long before the end of the challenge.

Our SaxoCell Retreat 2024 not only strengthened our professional bonds but also provided valuable insights and renewed enthusiasm for our collective goals. Thank you to everyone who was part of this event! It was great to get to know each other apart from desk and bench!

SaxoCell at the Long Night of Science

Once again this year in Dresden, science enthusiasts of all ages had the chance to get to know SaxoCell and learn about the latest advances in cell and gene therapy in discussions with our hub team.

Our tried-and-tested games and craft materials were available at our booth, including the colourful magnetic fishing game on CAR-T cell therapy and the entertaining immune cell quiz. We were delighted to welcome so many curious visitors at our stand!

The enthusiasm and curiosity of the visitors made the event truly special. Seeing so many people eager to learn about scientific advancements and participate in our activities was incredibly rewarding. We look forward to continuing this tradition and sharing more exciting developments at future events. Thank you to everyone who joined us and made the night unforgettable!

SaxoCell enters second funding phase!

SaxoCell is pleased to announce that it has been selected by the Federal Ministry of Education and Research (BMBF) and an independent expert jury for a second phase of funding in the Clusters4Future initiative.

We are very happy about this as it highlights the potential and achievements of SaxoCell, a pioneering cluster for innovative cell and gene therapies.

BMBF Clusters4Future press release

TU Dresden press release

University Leipzig press release

Fraunhofer IZI press release

Pressemitteilung des Fraunhofer IZI

BMBF Clusters4Future Meeting 2024

SaxoCell returns from Munich after this year’s Clusters4Future experience exchange.

Over two days, the seven clusters from both the first and second rounds of the competition had the opportunity to network and exchange ideas on key topics like cluster management, sustainability, and industrial collaborations. Representing us were SaxoCell spokesperson Frank Buchholz, along with Maren Henneken and Stefanie Binder from the Hub team.

This year’s hosts were Munich-based clusters MCube and CNATM. In addition to their thematic focuses on mobility and nucleic acid therapies, Best Practices on cluster sustainability, such as those presented by BioRN, were shared. During the panel discussion, participants received valuable insights into attracting young talent and skilled professionals, as well as transitioning Clusters4Future to the second funding phase. An open dialogue with representatives from the BMBF and Projektträger Jülich rounded off the meeting.

As in the past two years, the annual exchange provided an ideal opportunity to gain new insights, learn from one another, and reconnect with long-standing contacts. We’re looking forward to next year!

SaxoCell Retreat 2024

SaxoCell Retreat 2024

Unser zweitägiger SaxoCell-Retreat Anfang Juni war ein voller Erfolg und bot eine perfekte Mischung aus konstruktiven Diskussionen und spannenden Aktivitäten. Projektleitende und Forschende aus unseren Projekten und Plattformen, Mitglieder des SaxoCell-Hubs sowie Vertreter:innen unseres wissenschaftlichen Beirats kamen im Congress Hotel Chemnitz zusammen

Auf unserer Agenda standen aufschlussreiche Diskussionen, innovative Pitches und ein umfassender Ausblick auf unsere zukünftigen Projekte.

Den Höhepunkt des Retreats bildete die Team-Challenge, bei der wir acht Teams bildeten, um Spaghetti-Türme zu bauen – mit dem Ziel, den höchsten Turm zu erreichen – und so Kreativität und Teamwork zu fördern. Der Siegerturm war 70 Zentimeter hoch! Es gab auch einen Sieger der Herzen, der nicht so hoch, aber sehr stabil war und lange vor dem Ende der Zeitnahme stand.

Unser SaxoCell Retreat 2024 hat nicht nur unsere berufliche Verbundenheit gestärkt, sondern auch wertvolle Einblicke und neue Begeisterung für unsere gemeinsamen Ziele generiert. Vielen Dank an alle, die an dieser Veranstaltung teilgenommen haben! Es war großartig, sich abseits von Schreibtisch und Labortisch kennenzulernen!

SaxoCell auf der Langen Nacht der Wissenschaften

Auch in diesem Jahr hatten Wissenschaftsinteressierte jeden Alters in Dresden die Chance, SaxoCell kennenzulernen und die neuesten Fortschritte in der Zell- und Gentherapie in Gesprächen mit unserem Hub-Team zu erfahren.

Am Stand durften auch wieder unsere bewährten Spiel- und Bastelmaterialien ausprobiert werden, u.a das bunte Magnetspiel zur CAR-T-Zelltherapie und das unterhaltsame Immunzell-Quiz. Wir waren begeistert über die wieder so zahlreich erschienenen neugierigen Besucher!

Enthusiasmus und Neugierde der Besucher machten die Veranstaltung zu etwas ganz Besonderem. Es war unglaublich bereichernd, so viele Menschen zu sehen, die sich über wissenschaftliche Fortschritte informieren und an unseren Aktivitäten teilnehmen wollten. Wir werden diese Tradition fortsetzen und bei künftigen Veranstaltungen weitere spannende Entwicklungen präsentieren. Vielen Dank an alle, die dabei waren und diesen Abend unvergesslich gemacht haben!

SaxoCell startet in die zweite Förderphase!

SaxoCell wurde vom Bundesministerium für Bildung und Forschung (BMBF) und einer unabhängigen Fachjury für die zweite Förderphase im Clusters4Future-Wettbewerb ausgewählt!

Wir freuen uns sehr, denn diese Entscheidung unterstreicht das enorme Potenzial und die bisherigen Erfolge unseres Clusters für innovative Zell- und Gentherapien.

Pressemeldung BMBF Clusters4Future

Pressemitteilung der TU Dresden

Pressemitteilung der Universität Leipzig

Pressemitteilung des Fraunhofer IZI

BMBF Clusters4Future Erfahrungsaustausch 2024

SaxoCell kehrt begeistert zurück aus München vom diesjährigen Erfahrungsaustausch der Zukunftscluster.

An zwei Tagen hatten die sieben Cluster der ersten sowie die sieben Cluster der zweiten Wettbewerbsrunde die Möglichkeit, sich untereinander zu vernetzen und zu wesentlichen Themen wie Clustermanagement, Verstetigung und Industriekooperationen auszutauschen. Mit dabei waren unser SaxoCell-Sprecher Frank Buchholz sowie Maren Henneken und Stefanie Binder vom Hub-Team.

Gastgeber in diesem Jahr waren die beiden Münchner Cluster MCube und CNATM. Neben thematischen Schwerpunkten Mobilität und Nukleinsäuretherapien wurden Best Practices zur Clusterverstetigung, etwa von BioRN, vorgestellt. In der Paneldiskussion erhielten die Teilnehmenden wertvolle Impulse zur Nachwuchs- und Fachkräftegewinnung sowie zum Transfer der Zukunftscluster in die zweite Förderphase. Ein offener Austausch mit dem BMBF und dem Projektträger Jülich rundete das Meeting ab.

Wie in den beiden Jahren zuvor, bot auch dieser Erfahrungsaustausch eine ideale Gelegenheit, neue Eindrücke zu gewinnen, voneinander zu lernen und alte Kontakte aufzufrischen. Wir freuen uns auf das Treffen im nächsten Jahr!

Our Spring Sale Has Started

You can see how this popup was set up in our step-by-step guide: https://wppopupmaker.com/guides/auto-opening-announcement-popups/

Präzisionstherapie-Cluster

Weitere Informationen